PReventive Efficacy and Safety of rEbamipide on Nsaid Induced Mucosal Toxicity
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
To prove that the efficacy and safety of Mucosta® (Rebamipide) is non-inferior to those of
Cytotec® (Misoprostol), in terms of prevention of NSAID-induced gastric ulcer.